sulfasalazine has been researched along with Osteoporosis, Postmenopausal in 1 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA)." | 9.10 | Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. ( Beresford, JN; Bhalla, AK; Compston, JE; Kounali, D; Minaur, NJ; Vedi, S, 2002) |
| "To determine the effect of methotrexate (MTX) on bone mineral density (BMD) in rheumatoid arthritis (RA)." | 5.10 | Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. ( Beresford, JN; Bhalla, AK; Compston, JE; Kounali, D; Minaur, NJ; Vedi, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minaur, NJ | 1 |
| Kounali, D | 1 |
| Vedi, S | 1 |
| Compston, JE | 1 |
| Beresford, JN | 1 |
| Bhalla, AK | 1 |
1 trial available for sulfasalazine and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density; Dose-Respons | 2002 |